A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Jeffrey Bennett

Jeffrey Bennett

Study ID

Protocol Number: 23-0648

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers